Navigation Links
Bayer's Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community

WAYNE, N.J., Nov. 8, 2012 /PRNewswire/ -- At the National Hemophilia Foundation (NHF) Annual Meeting in Orlando today, Bayer HealthCare, the NHF and Save One Life celebrated the successful conclusion of the second annual Virtual Walk for Hemophilia, an engaging, online contest designed to raise awareness and funds for those living with bleeding disorders.

With an innovative spin on the fundraising walk idea, The Virtual Walk for Hemophilia ( employs a website where people interested in supporting those with hemophilia can virtually "walk" online.  Virtual walkers choose which NHF chapter they support, and create a customized avatar to represent themselves in the virtual walk.  At the time the Virtual Walk ended on November 6th, more than 32,000 people – those with and without hemophilia – had signed up. To put this number in perspective, the total number of people with hemophilia in the U.S. is currently estimated to be 15,000-20,000.

Bayer provided $30,000 in sponsorship funds to the national office of the NHF and an additional $33,500 in sponsorship funds to the five chapters with the greatest number of walkers, for a total of more than $60,000. Virtual walkers also had a chance to double the points they contributed to their chapter, by participating in an actual, physical fundraising walk.  This way, Bayer was able to provide a Virtual Walk, while also supporting chapters' own efforts at hosting fundraising walks throughout the country.

"Bayer's Virtual Walk was an exciting initiative for us this year," said Cindy Komar, Executive Director, Arizona Hemophilia Foundation.  "Encouraging people to sign up for the Walk was a great way for us to engage with our constituents, and it reenergized our whole team.  We're grateful for the sponsorship funds Bayer provided to us, and know that they will help us do even more for the hemophilia community in the coming year."

The chapters receiving sponsorship funds are:

First place: Arizona Hemophilia Association, with 9,004 walkers, received $15,000

Second place: Bleeding Disorders Alliance Illinois, with 8,714 walkers, received $10,000

Third place: Texas Central Hemophilia Association, with 6,833 walkers, received $5,000

Fourth place:  Nevada Chapter, National Hemophilia Foundation, with 3,625 walkers received $2,500

Fifth place: Nebraska Chapter, National Hemophilia Foundation, with 2,083 walkers, received $1,000

In addition to the sponsorship funds going to the NHF and its chapters, Bayer provided $7,000 in sponsorship funds to Save One Life, a non-profit, international organization that offers people and organizations the opportunity to sponsor a child or adult with a bleeding disorder in a developing country. In total, Bayer provided more than $70,000 in sponsorship funds to organizations in the hemophilia community.

According to Leslie Donato, Vice President/General Manager, Hematology, Bayer HealthCare, "In just its second year, The Virtual Walk for Hemophilia has become a fun and important way for the hemophilia community to come together.  We're gratified to see a strong response again this year, and are especially pleased to be able to provide this support to Save One Life and to the NHF and its participating chapters."

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classical hemophilia is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A is the most common type of hemophilia and is characterized by prolonged or spontaneous bleeding, especially into the, joints, muscles or internal organs. Approximately 400,000 people around the world have hemophilia. 

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare provides products for General Medicine, Hematology, Neurology, Oncology and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

BAYER® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statement

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Intended for U.S. media only

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Second Webinar in MedTech Trends Webcast Series on November 28, 2012; Navigating & Understanding the Sealing and Handling of Medical Microporous Materials
2. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
3. Cyberonics To Report Fiscal Year 2013 Second Quarter Results And Host Webcast And Conference Call On November 16, 2012
4. Encision Reports Second Quarter of Fiscal Year 2013 Results
5. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
6. Second Part of the Griffin Securities Analyst Interview with Unilife Corp. CEO is Now Available
7. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
8. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
9. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
10. Elbit Imaging Ltd. Announces Second Quarter Results for 2012
11. China Nepstar Chain Drugstore Reports Second Quarter 2012 Financial Results
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed ... 1-1 ). More than 3.7 billion people under the age of 50 – or ... to WHO's first global estimates of HSV-1 infection . , "The data shocks us ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
(Date:11/26/2015)... ... November 26, 2015 , ... The ... bioavailability and the need to integrate dose form selection in early phase drug ... the membership organization supporting and bringing together the UK’s emerging life sciences companies, ...
Breaking Medicine News(10 mins):